FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282947113> ?p ?o ?g. }

• W4282947113 endingPage "5330" @default.
• W4282947113 startingPage "5330" @default.
• W4282947113 abstract "Abstract Background: The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression after Gemcitabine-nab-Paclitaxel (GemPac) treatment indicating the need for more effective combination therapies for this highly recalcitrant disease. Earlier we showed that nuclear exporter protein exportin 1 (XPO1) is a valid therapeutic target in PDAC and selective inhibitor of nuclear export (SINE) selinexor (Sel), synergistically enhances the efficacy of GemPac in pancreatic cancer cells, spheroids, patient derived tumors and showed evaluable response in PDAC patients in a Phase I study. Here we investigated the mechanisms of this synergy utilizing PDAC cellular models in vitro and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) mouse model. Methods: We used single-nuclei RNA sequencing in KPC tumors, and poly A RNA sequencing in PDAC cells post sel-Gem-Pac treatment. Prioritized sn-seq and RNA-seq identified molecules were validated in in vitro or in the PDAC patient samples through siRNA mediated silencing, quantitative gene expression, cytotoxicity and related assays. Results: In KPC model, selinexor-GemPac caused statistically significant enhancement in survival compared to controls (p less than 0.05). Molecular analysis of residual KPC tumors showed re-organization of tumor stromal architecture, suppression of proliferation and nuclear retention of tumor suppressors. Histopathological analysis for Ki67 suggests comparatively lower rate of proliferation and enhanced nuclear accumulation of FOXO3a in the treated mice. Loosening of stroma and lowering of collagen fiber is also evident in treated mice from Picrosirius and Masson’s trichrome staining. Additionally, the KPC derived primary tumor cells showed reduced colony formation upon combination treatment. Sn-seq showed reduction in tumor cell heterogeneity (less cell clusters based on gene expression), CDK8, CD44 and Camk1d stem cell and EMT related genes alongside significant alterations in mitochondrial signaling after combination treatment. In cellular models, GO and GSEA analyses of RNA-seq data predicted DNA templated regulation of transcription and DNA replication associated genes in Sel or Sel-GemPac mediated growth inhibition. The top downregulated genes including drug resistant related gene PFN1 and HSP90 identified in Sel or Sel-GemPac treated PDAC cells from RNA-seq data were validated using RNAi and confirmed their role in synergy. Conclusions: Taken together Selinexor in combination with Gemcitabine-nab-Paclitaxel enhanced the survival of KPC mice through inhibition of well-connected tumor promoting molecules resulting in broad penetration in PDAC supporting signaling. A phase II study involving selinexor-gemcitabine combination in patients with metastatic PDAC is ongoing. Citation Format: Md. Hafiz Uddin, Sahar Bannoura, Yiwei Li, Husain Y. Khan, Amro Aboukameel, Mohammed N. Al-Hallak, Rafic Beydoun, Steve Kim, Yosef Landesman, Ramzi M. Mohammad, Anthony Shields, Asfar S. Azmi. Nuclear protein export inhibitor selinexor chemotherapy combination for pancreatic cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5330." @default.
• W4282947113 created "2022-06-16" @default.
• W4282947113 creator A5010443194 @default.
• W4282947113 creator A5011312785 @default.
• W4282947113 creator A5016599560 @default.
• W4282947113 creator A5016748416 @default.
• W4282947113 creator A5026049304 @default.
• W4282947113 creator A5037090507 @default.
• W4282947113 creator A5038465132 @default.
• W4282947113 creator A5044781652 @default.
• W4282947113 creator A5051531338 @default.
• W4282947113 creator A5057755017 @default.
• W4282947113 creator A5072203753 @default.
• W4282947113 creator A5089628525 @default.
• W4282947113 date "2022-06-15" @default.
• W4282947113 modified "2023-10-07" @default.
• W4282947113 title "Abstract 5330: Nuclear protein export inhibitor selinexor chemotherapy combination for pancreatic cancer therapy" @default.
• W4282947113 doi "https://doi.org/10.1158/1538-7445.am2022-5330" @default.
• W4282947113 hasPublicationYear "2022" @default.
• W4282947113 type Work @default.
• W4282947113 citedByCount "0" @default.
• W4282947113 crossrefType "journal-article" @default.
• W4282947113 hasAuthorship W4282947113A5010443194 @default.
• W4282947113 hasAuthorship W4282947113A5011312785 @default.
• W4282947113 hasAuthorship W4282947113A5016599560 @default.
• W4282947113 hasAuthorship W4282947113A5016748416 @default.
• W4282947113 hasAuthorship W4282947113A5026049304 @default.
• W4282947113 hasAuthorship W4282947113A5037090507 @default.
• W4282947113 hasAuthorship W4282947113A5038465132 @default.
• W4282947113 hasAuthorship W4282947113A5044781652 @default.
• W4282947113 hasAuthorship W4282947113A5051531338 @default.
• W4282947113 hasAuthorship W4282947113A5057755017 @default.
• W4282947113 hasAuthorship W4282947113A5072203753 @default.
• W4282947113 hasAuthorship W4282947113A5089628525 @default.
• W4282947113 hasConcept C104317684 @default.
• W4282947113 hasConcept C119056186 @default.
• W4282947113 hasConcept C121608353 @default.
• W4282947113 hasConcept C126322002 @default.
• W4282947113 hasConcept C142724271 @default.
• W4282947113 hasConcept C16930146 @default.
• W4282947113 hasConcept C202751555 @default.
• W4282947113 hasConcept C2780210213 @default.
• W4282947113 hasConcept C2780258809 @default.
• W4282947113 hasConcept C502942594 @default.
• W4282947113 hasConcept C55493867 @default.
• W4282947113 hasConcept C71924100 @default.
• W4282947113 hasConcept C86803240 @default.
• W4282947113 hasConceptScore W4282947113C104317684 @default.
• W4282947113 hasConceptScore W4282947113C119056186 @default.
• W4282947113 hasConceptScore W4282947113C121608353 @default.
• W4282947113 hasConceptScore W4282947113C126322002 @default.
• W4282947113 hasConceptScore W4282947113C142724271 @default.
• W4282947113 hasConceptScore W4282947113C16930146 @default.
• W4282947113 hasConceptScore W4282947113C202751555 @default.
• W4282947113 hasConceptScore W4282947113C2780210213 @default.
• W4282947113 hasConceptScore W4282947113C2780258809 @default.
• W4282947113 hasConceptScore W4282947113C502942594 @default.
• W4282947113 hasConceptScore W4282947113C55493867 @default.
• W4282947113 hasConceptScore W4282947113C71924100 @default.
• W4282947113 hasConceptScore W4282947113C86803240 @default.
• W4282947113 hasIssue "12_Supplement" @default.
• W4282947113 hasLocation W42829471131 @default.
• W4282947113 hasOpenAccess W4282947113 @default.
• W4282947113 hasPrimaryLocation W42829471131 @default.
• W4282947113 hasRelatedWork W1965851372 @default.
• W4282947113 hasRelatedWork W2094153719 @default.
• W4282947113 hasRelatedWork W2115579238 @default.
• W4282947113 hasRelatedWork W2126322332 @default.
• W4282947113 hasRelatedWork W2596055884 @default.
• W4282947113 hasRelatedWork W2885862304 @default.
• W4282947113 hasRelatedWork W3031244932 @default.
• W4282947113 hasRelatedWork W3031675857 @default.
• W4282947113 hasRelatedWork W4205828341 @default.
• W4282947113 hasRelatedWork W4281720666 @default.
• W4282947113 hasVolume "82" @default.
• W4282947113 isParatext "false" @default.
• W4282947113 isRetracted "false" @default.
• W4282947113 workType "article" @default.